52,675 Shares in Bioventus Inc. (NYSE:BVS) Acquired by Summit Global Investments

Summit Global Investments bought a new stake in Bioventus Inc. (NYSE:BVS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 52,675 shares of the company's stock, valued at approximately $553,000. Summit Global Investments owned approximately 0.06% of Bioventus at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BVS. Plato Investment Management Ltd acquired a new position in Bioventus in the 4th quarter valued at about $38,000. Virtus Fund Advisers LLC bought a new position in Bioventus during the 3rd quarter worth $42,000. Quest Partners LLC bought a new stake in shares of Bioventus in the third quarter valued at about $51,000. Quarry LP acquired a new position in shares of Bioventus in the third quarter valued at about $59,000. Finally, Arizona State Retirement System bought a new position in Bioventus during the fourth quarter worth about $109,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BVS has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised shares of Bioventus from an "underweight" rating to a "neutral" rating and boosted their price objective for the company from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group reissued a "buy" rating and set a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Remove Ads

Insider Buying and Selling

In other news, CEO Robert E. Claypoole sold 28,786 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the completion of the transaction, the chief executive officer now owns 64,964 shares of the company's stock, valued at approximately $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,161 shares of company stock worth $436,364. Corporate insiders own 32.90% of the company's stock.

Bioventus Price Performance

BVS traded down $0.06 on Friday, hitting $9.03. 251,471 shares of the stock were exchanged, compared to its average volume of 431,244. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a 12 month low of $3.90 and a 12 month high of $14.38. The firm has a market capitalization of $739.95 million, a price-to-earnings ratio of -14.80 and a beta of 0.86. The business has a 50-day moving average of $10.09 and a two-hundred day moving average of $10.98.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.